Sanofi’s RSV treatment nirsevimab awarded PIM status
PIM status was awarded on the basis of Phase IIb results of nirsevimab
Read More
Tag: PIM designation
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
